32 DIRECTORS’ REPORT Name: Steven Coffey Title: Non-Executive Director Qualifications: B. Comm, CA Experience and expertise: Steven is a Chartered Accountant and registered company auditor and has over 35 years of experience in the accounting and finance industry. Steven is a business and tax consultant with Charternet, the chartered accounting firm that merged with his accounting practice, Watkins Coffey Martin in February 2022. He is a director and principal of BC Advisory & Accountancy Services Pty Limited, a boutique accounting, tax and advisory practice. Other current directorships: Steven sits on the boards of a number of large private companies and private ancillary funds. He audits a number of large family companies and not-for-profit entities. Former directorships (last 3 years): Ansarada Group Limited (ASX: AND) formerly The Docyard Limited (ASX:TDY) Special responsibilities: Chair of Audit, Risk and Governance Committee, Member of Remuneration and Nomination Committee. Interests in shares: 991,993 ordinary shares Interests in options: 400,000 options with exercise price of $1.132 expiring 9 November 2024 Contractual rights to Options: None Name: Dr James Garner Title: Chief Executive Officer, Managing Director - resigned 30 April 2023, terminated 30 June 2023 Qualifications: MA, MBA, MBBS, BSc (Hons), MAICD Experience and expertise: Dr Garner is an experienced life sciences executive who has previously worked with companies ranging from small biotechs to multinational pharmaceutical companies such as Biogen and Takeda. His career has focused on regional and global development of new medicines from preclinical to commercialisation. Dr Garner is a physician by training and holds an MBA from the University of Queensland. He began his career in hospital medicine and worked for a number of years as a corporate strategy consultant with Bain & Company before entering the pharmaceutical industry. Prior to joining Kazia in 2016, he led R&D strategy for Sanofi in Asia-Pacific and was based in Singapore. Other current directorships: Antisense Therapeutics Limited (ASX:ANP) Former directorships (last 3 years): None Name: Ebru Davidson Title: Non-Executive Director - from 5 June 2023 Qualifications: BSc, JD (Hons), AGIA, GAICD Experience and expertise: Ms Davidson is a highly experienced corporate lawyer and is currently the General Counsel for QBiotics Group Limited, an unlisted public Australian life sciences company. Prior to this, Ms Davidson was a partner at national law firm Thomson Geer Lawyers and has over 14 years’ experience in equity capital markets, private and public mergers and acquisitions, corporate transactions and corporate governance. Ms Davidson also has extensive experience in advising listed and unlisted entities on compliance and regulatory matters working closely with the Australian Securities and Investment Commission and Australian Securities Exchange. Other current directorships: None Former directorships (last 3 years): None Interests in shares: None Interests in options: None
RkJQdWJsaXNoZXIy MjE2NDg3